Physician profile
Alberto Solache
NPI 1073033718
$373.57
in general payments reported to CMS, 2019-2025
14 companies · $58.06 in 2025
The $58.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $54.02 · 2021: $35.86 · 2022: $37.57 · 2023: $77.33 · 2024: $111 · 2025: $58.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $110.29 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Abbott Laboratories | $40.45 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi Pasteur INC. | $29.12 | 2021-2023 | |
| Ironshore Pharmaceuticals INC. | $27.04 | 2020 | |
| Pfizer INC. | $24.49 | 2020-2022 | |
| Novo Nordisk INC | $20.96 | 2021 | |
| Hologic Sales and Service, LLC | $20.56 | 2024 | Aptima |
| Seqirus USA INC | $16.42 | 2024 | Flucelvax |
| Exact Sciences Corporation | $15.15 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $14.51 | 2024 | Evenity, Prolia |
| Ultragenyx Pharmaceutical INC. | $14.47 | 2023 | |
| Mylan Specialty L.P. | $14.26 | 2020 | |
| Dexcom, INC. | $14.14 | 2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Solache listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.